You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
博雅生物(300294.SZ):博雅(廣東)已償還6000萬元原料血漿採購款
格隆匯 09-28 13:12

格隆匯9月28日丨博雅生物(300294.SZ)公佈,經公司第六屆董事會第二十三次會議、第六屆監事會第二十次會議,以及2019年第一次臨時股東大會審議,通過了《關於採購廣東丹霞生物製藥有限公司原料血漿暨關聯交易的議案》,公司向丹霞生物(現更名為:博雅生物製藥(廣東)有限公司,下稱“博雅(廣東)”)採購不超過500噸的原料血漿,採購價格不超過165萬元/噸,金額不超過8.25億元,公司與博雅(廣東)簽訂了《原料血漿供應框架協議》。

2020年9月14日,公司《關於採購原料血漿進展的公告》披露了履約進展以及公司應對目前履行《原料血漿供應框架協議》遇到的障礙所採取的措施情況。

目前,博雅(廣東)在配合公司實施資金保障措施的同時,也針對暫不能供漿這一現狀,開始償還預付款。截至該公告披露日,博雅(廣東)向公司償還6000.00萬元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account